SEC For	rm 4																			
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549														OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					ENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										HIP	Estin	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person* Patel Sujal M						2. Issuer Name and Ticker or Trading Symbol <u>Nautilus Biotechnology, Inc.</u> [ NAUT ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner V Officer (give title Other (specify					
	(Last)(First)(Middle)C/O NAUTILUS BIOTECHNOLOGY, INC.2701 EASTLAKE AVENUE EAST						3. Date of Earliest Transaction (Month/Day/Year) 02/25/2022									X Officer (give the below) below) below) CEO, President, and Secretary				
(Street) SEATTLE WA 98102					4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)						10 SI	ouritio	- 40	auirad	Die	-nosod c	of or	Bor	oficially						
Table I - Non-Deriv   1. Title of Security (Instr. 3)   2. Trans. Date (Month/I)				actio	'n	2A. Deemed Execution Date, if any (Month/Day/Yea		e, 3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		d (A) or	5. Amour	s Illy ollowing	Form (D) or	r Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) o (D)		Price	Transaction(s) (Instr. 3 and 4)				( )	
			Table II -						uired, D s, option						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		I. Fransaction Code (Instr. 3)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exp Expiration (Month/Da	e	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		es Security	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securiti Benefici Owned Followir Reporte	ve es ially ng d	y Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
				C	ode	v			Date Exercisabl		Expiration Date	n Or Num		Amount or Number of Shares		Transac (Instr. 4)				

## Explanation of Responses:

\$3.78

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is February 25, 2022.

(1)

02/25/2032

Common

Stock

400,000

**Remarks:** 

Stock Option

(Right to Buy)

## /s/ Matthew B. Murphy

\*\* Signature of Reporting Person

\$<mark>0</mark>

400,000

02/25/2022

Date

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/25/2022

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A

400,000

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.